title: [Evaluation on the effect of Benazepril for hypertension through postmarketing surveillance].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of Benazepril used among the essential hypertensives.
  
  
  METHODS
  1 831 essential hypertensive patients aged 35 to 75 were randomly selected from a community and followed for 18 months. The level of blood pressure, status of taking Benazepril and side effects were sequencially collected.
  
  
  RESULTS
  1/3 of the patients had taken antihypertensive drug before the study and the rate of compliance was over 96%. The effective rate of Benazepril was 73.6% at three months and increased to 84.7% at 18 months. Comparing with the baseline data, SBP and DBP declined 10.8 mmHg and 6.7 mmHg respectively. The rate of side effect was 22.7%. Cough was most commonly seen among side effects. The peak of first recording on side effect occurred at three months including 60% of them mild.
  
  
  CONCLUSIONS
  Results showed that Benazepril had good efficacy and safety for the essential hypertension patients in a long-term observation.
authors.affiliation: Department of Epidemiology, Beijing Medical University, Beijing 100083, China.
authors.forename: W
authors.initials: W
authors.lastname: Cao
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Hu
authors.forename: S
authors.initials: S
authors.lastname: Zhan
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.forename: P
authors.initials: P
authors.lastname: Li
authors.forename: T
authors.initials: T
authors.lastname: Wu
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: T
authors.initials: T
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D003371:Cough / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001552:Benzazepines; C044946:benazepril